Retatrutide: What the Phase 1–3 Clinical Trial Series Shows, and What Is Still Unknown

RESEARCH · RETATRUTIDE

Retatrutide: What the Phase 1–3 Clinical Trial Series Shows, and What Is Still Unknown

Retatrutide (development code LY3437943) is a single synthetic peptide that activates three receptors: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon. It is one of the most closely watched investigational molecules in metabolic research, and over the past few months the first phase 3 results have reached the peer-reviewed literature. This article summarises what those publications report, what they do not, and why the origin of a material matters. Our earlier post, What is Retatrutide 10mg at PurixLab, is a short product FAQ; this one is a literature overview. PurixLab’s Retatrutide 10mg is supplied as a lyophilized research vial for laboratory research use only.

From discovery to phase 1

The discovery paper describes LY3437943 as a triple agonist peptide with balanced glucagon-receptor and GLP-1-receptor activity and somewhat more GIP-receptor activity in vitro. In obese mice it lowered body weight and improved glycaemic control, and the authors reported that glucagon-receptor-mediated energy expenditure added to the calorie-intake reduction driven by GIP and GLP-1 receptors. In a phase 1 single-ascending-dose study its pharmacokinetics supported once-weekly dosing, and weight reduction persisted up to day 43 after a single dose [1]. A 12-week phase 1b study in 72 people with type 2 diabetes reported a half-life of about 6 days, mostly gastrointestinal adverse events, significant glucose and HbA1c reductions at the three highest doses, and an apparently dose-dependent body-weight reduction [2].

Phase 2: obesity, diabetes and liver fat

  • Obesity. In 338 adults over 48 weeks, mean weight change in the highest-dose group was −24.2% versus −2.1% with placebo. Gastrointestinal events were dose-related and partly mitigated by a lower starting dose; heart rate rose dose-dependently, peaking at 24 weeks and declining thereafter [3].
  • Type 2 diabetes. In 281 participants, HbA1c fell significantly versus placebo at 24 weeks in all but the lowest-dose group, and two of the higher-dose groups also exceeded the dulaglutide comparator. At 36 weeks, weight fell by 16.94% in the highest-dose group versus 3.00% with placebo [4].
  • Body composition. A DXA substudy found significant total fat-mass reductions versus placebo, and the authors reported a proportion of lean-mass loss similar to other obesity treatments [5].
  • Liver fat. In 98 participants with MASLD and at least 10% liver fat, relative liver-fat change at 24 weeks was −82.4% in the highest-dose group versus +0.3% with placebo; 86% of that group reached normal liver fat (<5%) [6].

Phase 3: what has been published

The TRIUMPH programme comprises four phase 3 trials in more than 5,800 participants, covering obesity, obstructive sleep apnoea, knee osteoarthritis and a cardiovascular-disease population [7]. Published results so far:

  • TRIUMPH-1 (obesity without diabetes; 2,339 randomised; 80 weeks; NEJM, online September 2026). Mean weight change was −17.6%, −23.7% and −25.0% across three dose groups versus −3.9% with placebo. Prespecified sub-populations with knee osteoarthritis and sleep apnoea also improved on pain score and apnoea–hypopnoea index. The most common adverse events were gastrointestinal [8].
  • TRIUMPH-2 (obesity with type 2 diabetes; 1,152 randomised; 80 weeks; Lancet). Weight change was −11.9%, −16.8% and −18.8% versus −5.1% with placebo. Diarrhoea occurred in 27–34% of retatrutide groups versus 13% with placebo, nausea in 14–28% versus 8%, and hypotension and dysaesthesia were more frequent than with placebo. Permanent discontinuation due to adverse events or death was 12% and 8% in the two higher-dose groups, 4% in the lowest and 5% with placebo [9].
  • TRANSCEND-T2D-1 (type 2 diabetes on diet and exercise; 537 randomised; 40 weeks; Lancet). HbA1c fell by 1.69–1.94% versus 0.81% with placebo, and weight by 11.5–15.3% versus 2.6% [10].

We found no published report of TRIUMPH-3 or TRIUMPH-4 in PubMed as of 2026-10-09.

What remains unknown

  • Duration. The longest treatment period in the reports cited here is 80 weeks [8,9]. Long-term safety, durability and outcomes data are not available in them.
  • Tolerability signals. Heart-rate effects in phase 2 [3] and hypotension and dysaesthesia in TRIUMPH-2 [9] are the kind of findings that need longer follow-up.
  • Funding and independence. The phase 2 and 3 reports cited here state Eli Lilly as funder [3,9,10]; independent replication is still to come.
  • Status. The 2026 trial reports describe retatrutide as under investigation [9]. Health Canada’s advisories say that products labelled “For Research Use Only – Not for Human Consumption” are not exempt from regulatory requirements [11]. Clinical trial results were generated in regulated trials under medical supervision; they say nothing about the contents of any other vial.

Why independent verification of materials matters

An Australian laboratory analysis of three products sold as “10 mg retatrutide” confirmed the expected molecular weight in each, but measured peptide content ranged from 5.13 mg (51.3% of label) to 19.0 mg (190.0%). It was a very small sample, but it illustrates why batch documentation and independent analytical testing are central to responsible research sourcing [12].

General laboratory storage background

Laboratories should always follow the product label, any batch documentation and their own approved procedures. As general background, peptide suppliers’ technical guides describe broadly similar practice for lyophilized (freeze-dried) peptides:

  • Keep it dry, dark and cold. Lyophilized peptides should be kept away from heat, light and moisture; for longer-term storage, guides commonly recommend about −20 °C [13,14].
  • Avoid condensation. Let a cold vial reach room temperature, ideally in a desiccator, before opening, then reseal promptly [14].
  • Limit freeze–thaw cycles. Aliquoting by planned experiment reduces freeze–thaw cycles and air exposure [13].
  • Solutions are short-lived. Peptides in solution have a much shorter shelf life than the dry powder [13,14].

This is general laboratory information, not a protocol, and it contains no instructions for human use.

Retatrutide 10mg at PurixLab

Retatrutide 10mg: a labelled lyophilized research vial with 10mg per vial, C$119 per vial (CAD, before tax), supplied for laboratory research only. Batch documentation is available on request. Product page: purixlab.com/product/retatrutide-10mg/.

PurixLab ships within Canada only, from stock held in Toronto. Standard shipping is C$15, and shipping is free when the product subtotal is C$200 or more after discounts. Orders outside the GTA ship by Canada Post Xpresspost. Prices are in CAD and taxes are calculated from your shipping address at checkout.

In Toronto and the GTA, our own team delivers orders the same day or the next day. There is no fixed GTA delivery fee: after you place your order, we email you to confirm the delivery time and any delivery charge, and then you pay. There is no storefront or local pickup.

Payment is by Interac e-Transfer (instructions are shown at checkout) or by cryptocurrency through Plisio (Bitcoin, Ethereum, USDT and more): choose Plisio at checkout and you are sent to a secure Plisio payment page after placing the order. Codes: WELCOME10 takes 10% off eligible orders below C$400; PURIX20 takes 20% off eligible orders of C$400 or more before discount and tax. One offer per order; offers do not stack.

For laboratory research use only. Not for human or veterinary use, not for consumption, injection or application to skin, and purchasers must be 18 or older. The studies summarised above describe specific materials in published research; they are not claims about any PurixLab product.

View Retatrutide 10mg

Questions or batch documentation requests: [email protected] · Shipping & Delivery · Toronto & GTA delivery · PurixLab FAQ

References

  1. Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234-1247.e9. PubMed 35985340 · doi:10.1016/j.cmet.2022.07.013
  2. Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400(10366):1869-1881. PubMed 36354040 · doi:10.1016/S0140-6736(22)02033-5
  3. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. PubMed 37366315 · doi:10.1056/NEJMoa2301972
  4. Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529-544. PubMed 37385280 · doi:10.1016/S0140-6736(23)01053-X
  5. Coskun T, Wu Q, Schloot NC, et al. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. Lancet Diabetes Endocrinol. 2025;13(8):674-684. PubMed 40609566 · doi:10.1016/S2213-8587(25)00092-0
  6. Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30(7):2037-2048. PubMed 38858523 · PMC11271400 · doi:10.1038/s41591-024-03018-2
  7. Giblin K, Kaplan LM, Somers VK, et al. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials. Diabetes Obes Metab. 2026;28(1):83-93. PubMed 41090431 · PMC12673447 · doi:10.1111/dom.70209
  8. Jastreboff AM, Kaplan LM, Davies MJ, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity (TRIUMPH-1). N Engl J Med. 2026 Sep 29 (online ahead of print). PubMed 42814954 · doi:10.1056/NEJMoa2604169
  9. Bellido V, le Roux CW, Ekinci EI, et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Lancet. 2026;408(10563):1455-1472. PubMed 42810372 · doi:10.1016/S0140-6736(26)01861-1
  10. Bajaj HS, Welch M, Shah P, et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Lancet. 2026;407(10546):2402-2413. PubMed 42250575 · doi:10.1016/S0140-6736(26)00967-0
  11. Health Canada. Think twice before injecting peptides bought online: unauthorized products can seriously harm you (public advisory, 2026-04-09). Health Canada advisory
  12. Piatkowski T, Craven A, Cornell S, et al. Composition and Labelling Accuracy of Products Sold as Retatrutide in Australia. Drug Alcohol Rev. 2026;45(6):e70231. PubMed 42559975 · PMC13445994 · doi:10.1111/dar.70231
  13. GenScript. Peptide Storage and Handling Guidelines (technical resource). GenScript
  14. AAPPTec. Handling and Storage of Peptides — FAQ (technical resource). AAPPTec

Leave a Comment

Your email address will not be published. Required fields are marked *